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Abstract Leukocyte immunoglobulin-like receptors (LILR)
are expressed mostly on myelomonocytic cells where they are
mediators of immunological tolerance. Two LILR genes,
LILRA3 and LILRA6, exhibit marked copy number variation.
We assessed the contribution of these genes to atopic derma-
titis (AD) by analysing transmission in 378 AD families. The
data indicated that copies of LILRA6 were over-transmitted to
affected patients. They are consistent with a contribution of
LILR genes to AD. They could affect the equilibrium between
activating and inhibitory signals in the immune response.
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Introduction
Atopic dermatitis (AD) is a chronic disease that affects around
10–20 % of children in western countries. It is characterised
by pruritus and skin inflammation and is frequently associated
with food allergies and asthma (Werfel et al., 2014).
There are several factors that contribute to the development
of AD such as environmental conditions (Zutavern et al.,
2005; Roduit et al., 2011; Silverberg et al., 2011; Caroline et
al., 2012), dysfunction of the skin barrier (Cork et al., 2009;
Agrawal and Woodfolk, 2014) and viral and bacterial skin
infections (Cho et al., 2001). AD can be developed when there
is an abnormal or sustained activation of the skin innate im-
mune system (McGirt and Beck, 2006; Maintz and Novak,
2011; Kasraie and Werfel, 2013, Kuo et al., 2013).
Additionally, genetic factors have been associated to the de-
velopment and vertical transmission of AD (Söderhäll et al.,
2007; Irvine et al., 2011). Alterations in the function and sig-
nalling pathways and polymorphisms in Toll-like receptor 2
(TLR2) have been associated with the development of AD
(Potaczek et al., 2011; Yu et al., 2015) whilst Killer
immunoglobulin-like receptor (KIR), specifically
KIR2DS1, seems to be associated with protection from
AD (Niepiekło-Miniewska et al., 2013).
Leukocyte immunoglobulin-like receptors (LILR) are also
innate immune receptors encoded, like KIR, within the leuko-
cyte receptor complex (LRC) on chromosome 19q13.4
(Barrow and Trowsdale, 2008). LILR display limited genetic
diversity (Young et al., 2001) apart from LILRB3 and LILRA6,
which exhibit considerable sequence polymorphism in the
extracellular domains and LILRA3 and LILRA6 which also
show variation in the number of copies (Torkar et al., 2000;
Sudmant et al., 2010; Bashirova et al., 2014; Lopez-Alvarez et
al., 2014). LILR can regulate the activity of TLR (Brown et al.
2004, Cao et al., 2009) and mediate immunological tolerance
(Manavalan et al., 2003; Kim-Schulze et al., 2006; Anderson
and Allen, 2009). Currently, there is no data about the role of
LILRB3 and LILRA6, although their recently discovered in-
teraction with a cytokeratin 8-associated ligand suggests they
could shape local inflammatory responses to epithelial tu-
mours (Jones et al., 2016). LILRA3 has been described as a
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soluble receptor that binds HLA class I molecules and it has
been associated with multiple sclerosis (An et al., 2016), sys-
temic lupus erythematosus and Sjögren’s syndrome (Du et al.,
2014).
Despite the strong genetic component together with the
implication of the innate immune response inAD, in particular
TLR and KIR receptors, there is no data available considering
the association of LILR genes with AD. This is a prelim-
inary study to assess the impact of the variability of
LILRA3 and LILRA6 loci among members of 378 AD
families.
DNA samples, obtained from the UK DNA Banking
Network (DBN), consisted of 1482 Caucasoid individuals
from 378 families. Three hundred fifty-eight children had ac-
tive AD. The childrens’ mean age was 10 years (±4 years).
One hundred ninety-six (55 %) were male subjects (Sandford
et al., 1995; Morar et al., 2006). Children lacking signs of
disease were classified as unaffected. No significant associa-
tion between sex or age and development of AD was found
(p > 0.05). All subjects were of initial European ancestry and
gave their informed consent.
LILRA3 and LILRA6 copy number was determined by
quantitative PCR on genomic DNA extracted using standard
techniques. Forward and reverse primers and a dual-labelled
probe were designed to specifically amplify LILRA3 and
LILRA6 genes avoiding any allelic variation identified to date
(Lopez-Alvarez et al., 2014). Sequences were analysed for
specificity using the primerBLAST tool from the National
Centre for Biotechnology Information (http://www.ncbi.nlm.
nih.gov/tools/primer-blast). In addition, all reactions
contained specific primers and a probe for the STAT6 gene,
which has two copies per diploid human genome, and was
used as an endogenous reference gene. All reactions were
performed in quadruplicate for each sample to increase the
accuracy of copy number scoring. Positive controls for each
copy number type from IHW cell lines (Lopez-Alvarez et al.,
2014) and a negative non-template control were included on
each microtiter plate.
A total of 10 ng of genomic DNA was amplified
under the following PCR conditions: 5 min at 95 °C,
followed by 40 cycles of 95 °C for 15 s and 66 °C for
50 s, followed by 10 s at 40 °C, using the LightCycler
480 System (Roche Diagnostics Ltd., Burgess Hill,
UK). LILR copy number was determined by a quantita-
tive PCR comparative Ct method (Schmittgen and
Livak, 2008).
Family-based association analysis was carried out using the
transmission disequilibrium test (TDT) to examine the trans-
mission rates for the number of copies of LILRA3 and LILRA6
from parents to affected offspring. The analysis was per-
formed using Unphased software (Dudbridge, 2008) which
implements maximum-likelihood inference on genotype ef-
fects. In addition, FBAT software version V2.04 was used to
perform the association analyses using the additive model and
bi-allelic mode (data not shown).
First of all, we determined the variation in the number of
copies of LILRA3 and LILRA6 loci in the cohort of families.
The number of copies of LILRA3 per haplotype varied from 0
to 2 copies, whilst LILRA6 showed between 0 and 4 copies.
One copy was the most frequent for LILRA3 and
LILRA6 with frequencies over 70 % in both cases
(Table 1). The frequencies obtained per diploid genome
matched very closely to previously reported (data not
shown, Lopez-Alvarez et al., 2014).
Regarding the transmission of LILRA3 and LILRA6
among families, in relation to disease (Table 2), LILRA6
showed a significant association with AD (p = 0.0025).
There was a slight over-transmission of one copy of
LILRA6 to affected children (0.7197 vs. 0.6842,
p = 0.002, OR 1.45, 95 % CI 1.14–1.85), suggesting that
the presence of one copy of LILRA6 on each chromosome
could be a risk factor for AD. In contrast, haplotypes
missing LILRA6 (0 copies per haplotype) were under-
transmitted (0.0636 vs. 0.0933). Analysis of the data with
FBAT software (see Methods) also revealed the above
associations (data not shown).
Table 1 Frequencies of the
number of copies in LILRA3 and
LILRA6 per haplotype
Marker Number of copies Total AD P value
Unaffected Affected
LILRA3 0 613 (20.7) 401 (20.9) 212 (20.3) 0.714
1 2339 (78.9) 1512 (78.7) 827 (79.4)
2 12 (0.4) 9 (0.5) 3 (0.1)
LILRA6 0 217 (7.3) 143 (7.4) 74 (7.1) 0.948
1 2107 (71.2) 1370 (71.3) 737 (70.7)
2 617 (20.8) 395 (20.6) 222 (21.3)
3 19 (0.6) 12 (0.6) 7 (0.7)
4 4 (0.1) 2 (0.1) 2 (0.1)
Number of copies denotes copies per haplotype. Frequencies are given in the parentheses
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In several families, the transmission of LILRA3 and
LILRA6 genes was consistent with duplication of these
genes on a chromosome. Twelve individuals (~1 %),
distributed among five families, would have two copies
of LILRA3 on the same chromosome, being the only
possible arrangement to explain the segregation through
the next generation. The incidence of two copies of
LILRA6 on the same chromosome was more frequent
(~7 %). In those individuals with a higher number of
copies of LILRA6, the number of copies was not evenly
distributed on each chromosome. For example, some
possessed four copies on one chromosome and two on
the other.
This is the first study considering the effect of LILR
receptors on the development of AD. We analysed the
variation in the number of copies of LILRA3 and
LILRA6 genes in a series of a family trios suffering
from the disease.
AD is characterised by a Th2-mediated response
(Novak et al., 2003; Chu et al., 2011) triggered by den-
dritic cells (DC) (Moser and Murphy, 2000). LILRA3 is a
soluble protein which seems to be an antagonist of inhib-
itory LILRs (Poon et al., 2005) and could also have an
important role in establishing Th1 or Th2 responses
(Thomas et al., 2010). The lack of LILRA3 could lead
to the early conclusion of the antiviral defence, supporting
chronic infection and favouring the development of auto-
immune diseases, like multiple sclerosis and Sjögren’s
syndrome (Pender, 2009; Thomas et al., 2010). Unlike
in autoimmune diseases (Wiśniewski et al., 2013; Du et
al., 2014), the number of copies of LILRA3 was not sig-
nificantly different between AD unaffected and affected
individuals without considering their relatedness (Table
1) or in transmission frequencies of gene copies between
unaffected and affected offspring.
LILRA6 is an activating receptor encoded by a
polymorphic gene that shows variation in the number
of copies (Bashirova et al., 2014; Lopez-Alvarez et al.,
2014). Like LILRA3, there were no differences in the
number of copies between unaffected and AD affected
individuals but we observed significant differences in
the transmission of the number of copies of LILRA6
within families (Table 2). The results showed a modest
over-transmission of one copy of LILRA6 whilst hap-
lotypes lacking this gene were under transmitted. These
results suggest that the lack of LILRA6 could be a
protective factor against AD. Indeed, the activating na-
ture of this receptor upon binding with the specific
ligand could trigger the immune response and promote
the development of atopic dermatitis. In contrast, two
or more copies of LILRA6 showed no influence on
disease risk. The reason for this is unclear at present
but it could mean that the paralogs are disrupted genes
or that they differ functionally.
LILRA6 CNV may influence the level of the activating
receptor on the cell surface, potentially affecting signalling
upon LILRB3/A6 ligation (Bashirova et al., 2014). Thus, the
variation observed here could affect the equilibrium between
activating and inhibitory signals and the balance of the im-
mune response. An alternative explanation could be that the
effects we observe reflect linked genes such as KIR on NK
cells. In this context, some HLA class I alleles, such as HLA-
B*57:01 and HLA-B*44:02 which are ligands for KIR recep-
tors, have been associated with AD in several GWAS studies
(Hirota et al., 2012; Weidinger et al., 2013). Also, KIR2DS1
may be a protective factor in AD, although its effect remains
unclear (Kusnierczyk, 2013).
In conclusion, we have assessed the variation in the number
of copies of LILRA3 and LILRA6 in a series of AD family
trios. Among them, only the transmission of one copy of
LILRA6 within families was potentially related to the devel-
opment of AD. Further studies should be done in order to
clarify the role of LILRA6 and its possible ligands in the
development of AD.
Table 2 TDT results for LILRA3
and LILRA6 in AD affected
families
Number of copies Trans Untrans T-Freq U-Freq P value
LILRA3 0 157 432 0.2224 0.2006 0.980518
1 547 1715 0.7748 0.7962
2 2 7 0.002833 0.00325
LILRA6 0 44 200 0.06358 0.09325 0.00254137
1 498 1467 0.7197 0.6842
2 145 462 0.2095 0.20155
3 4 14 0.00578 0.00653
4 1 1 0.001445 0.0004664
Number of copies denotes copies of the gene on the same haplotype. Trans is the estimated count of this haplotype
to affected offspring. Untrans is the estimated number of non-transmissions of this haplotype. TDT-like counts of
transmitted and untransmitted allelic copies are not given as they cannot be accurately defined when parents are
missing. T-Freq is the frequency of the haplotype in affected offspring. U-Freq is the frequency of the haplotype
among untransmitted haplotypes. P value is the overall significance for the locus
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